Home

Convener, collaborator, catalyst in the fight against cancer.

At Project Data Sphere®, we believe in breaking down barriers to cancer clinical trial data sharing — barriers that historically have kept valuable trial data from ultimately benefitting the patients who so selflessly participate in them. By aggregating trial data from biopharmaceutical companies, academic medical centers, and government organizations and making it freely available on our open-access platform, we have established ourselves as a premier resource for the global oncology research community. Our deep relationships with renowned oncology experts allow us to convene research collaborations that leverage the power of pooled clinical trial data and which ultimately position PDS to be a catalyst for the discovery of urgently needed new treatments while helping to make cancer trials faster, more effective, and less expensive.

Data Providers

research-photo.jpg

External Control Arm

Conducting late-stage cancer trials without the need for a comparator arm could reduce patient enrollment time, cut costs, and preserve patient availability for other trials. Project Data Sphere's External Control Arm program is focused on making this a reality for cancer trials.

Images and Algorithms

Manually quantifying the size of solid tumors is both slow and subject to inter-reader variability. The Images and Algorithms program was created to accelerate these measurements and reduce inter-reader variability by developing a machine-learning algorithm to augment independent radiologist readings.

Rare Tumor Registries

Project Data Sphere’s MCC Tumor Registry is a prototype for a reliable source of publicly accessible information on rare diseases. Aggregating prospective patient-level data from multiple clinical sites, the registry offers an important source of information for natural history studies and, potentially, proof-of-concept for using real-world evidence in the drug-approval process.

Immune-Related Adverse Events

Project Data Sphere is driving solutions that remove barriers to data sharing in order to improve patient outcomes and expand cancer treatment options. The Immune-Related Adverse Events research program supports initiatives dedicated to improving the safety and efficacy of powerful immunotherapy treatments and decreasing the impact of associated adverse events.

ROADBLOCKS TO DATA REUSE CAN BE OVERCOME

Clinical trial volunteers give consent to their data being used in primary and secondary research but less than 1% of it can be found for reuse on controlled access platforms. Why? What are the roadblocks and how can we do more to recognize patients’ desires and advance treatment through their contributions?

Latest News

Symposium X to focus on sharing oncology data

Register now for the latest in the series of symposia co-sponsored by the US Food and Drug Administration and Project Data Sphere. This year's event on September 23, 1-4 pm EDT, will focus on data sharing and reuse of oncology clinical research data – policies and practices that enable greater access and utilization of patient level data.

Home

More about the Project Data Sphere platform

Data Providers

Sponsored Research